Franklin Genomic Advancements ETF (HELX)

Assets	$12.28M
Expense Ratio	0.50%
PE Ratio	36.24
Shares Out	400,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	+1.18%

Volume	1,618
Open	30.44
Previous Close	30.84
Day's Range	30.17 - 30.44
52-Week Low	28.30
52-Week High	33.98
Beta	1.08
Holdings	65
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

43.26% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	5.80%
Vertex Pharmaceuticals Incorporated	VRTX	5.37%
Samsung Biologics Co.,Ltd.	207940	4.88%
Eli Lilly and Company	LLY	4.58%
Thermo Fisher Scientific Inc.	TMO	4.35%
Danaher Corporation	DHR	4.15%
Krystal Biotech, Inc.	KRYS	4.01%
Medpace Holdings, Inc.	MEDP	3.92%
Regeneron Pharmaceuticals, Inc.	REGN	3.60%
BioNTech SE	BNTX	2.60%